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Abstract
Background: Microsatellite instability (MSI) refers to mutations in short motifs of tandemly
repeated nucleotides resulting from replication errors and deficient mismatch repair (MMR).
Colorectal cancer with MSI has characteristic biology and chemosensitivity, however the molecular
basis remains unclarified. The association of MSI and MMR status with outcome and with
thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) expression in colorectal
cancer were evaluated.
Methods: MSI in five reference loci, MMR enzymes (hMSH2, hMSH6, hMLH1 and hPMS2),
thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) expression were assessed
in paraffin embedded tumor specimens, and associated with outcome in 340 consecutive patients
completely resected for colorectal cancer stages II-IV and subsequently receiving adjuvant 5-
fluorouracil therapy.
Results: MSI was found in 43 (13.8%) tumors. Absence of repair protein expression was assessed
in 52 (17.0%) tumors, which had primarily lost hMLH1 in 39 (12.7%), hMSH2 in 5 (1.6%), and
hMSH6 in 8 (2.6%) tumors. In multivariate analysis MSI (instable) compared to MSS (stable) tumors
were significantly associated with lower risk of recurrence (hazard ratio (HR) = 0.3; 95% CI: 0.2–
0.7; P = 0.0007) and death (HR = 0.4; 95% CI: 0.2–0.9; P = 0.02) independently of the TS and DPD
expressions. A direct relationship between MSI and TS intensity (P = 0.001) was found, while there
was no significant association with DPD intensity (P = 0.1).
Conclusion: The favourable outcome of MSI colorectal carcinomas is ascribed mainly to the
tumor biology and to a lesser extent to antitumor response to 5-fluorouracil therapy. There is no
evidence that differential TS or DPD expression may account for these outcome characteristics.
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Colorectal cancer is the fourth most common malignant
tumor in Western Europe and Northern America affecting
7% of the population and ranks as the second leading
cause of cancer-related mortality [1].
The majority of colorectal cancers display aneuploidy
appearing as chromosomal anomalies, whereas the
remainder that constitutes 15–20% of these cancers is
characterized by microsatellite instability (MSI) [2-6].
Microsatellites are DNA sequences in which a short motif
of 1–5 nucleotides are tandemly repeated ten to hundred
times. Microsatellites are prone to mutation during repli-
cation due to transient split of the two helical strands and
slippage of the DNA polymerase complex at reannealing,
which generate an insertion or deletion loop depending
on slippage direction. Unless such mismatch is corrected,
the loss or gain of repeated units on the daughter strand
results in length variation termed microsatellite instability
(MSI) [7].
The mismatch repair (MMR) is performed by the proteins
hMSH2 heterodimerized with hMSH6 for recognition of
a loop of few mismatched extrahelical nucleotides. Upon
assemblage this complex interact with another het-
erodimeric complex, composed of hMLH1 and hPMS2
[8].
Deficient MMR that arise in sporadic colorectal cancer is
nearly always due to an epigenetic biallelic hypermethyl-
ation of the hMLH1 gene promoter. In addition, MMR
deficiency may result from genetic disorders, caused by an
inherited germ-line mutation of one allele followed by an
acquired alteration of the wild-type allele leading to inac-
tivation of one of the three main MMR genes (MLH1,
MSH2, and MSH6) [7].
While most of the half million microsatellite sequences
scattered in the human genome are located within
untranslated regions, in which MSI is assumed to be with-
out significance to expression, a number of genes involved
in mitosis and apoptosis carry microsatellites in their
encoding regions [9]. MMR deficiency may promote
malignant transformation as it allows accumulation of
microsatellite insertion/deletion mutations, leading to
MSI-driven inactivation of genes having key regulatory
functions [10]. Besides being pathogenetic to malignant
transformation MSI also characterises a subset of colorec-
tal cancers with characteristic biology and chemosensitiv-
ity. Accordingly, in pooled analysis of patients with local
and advanced disease high-frequency MSI (MSI-H) was
associated with a favorable prognosis compared to micro-
satellite stable/low-frequency MSI (MSS/MSI-L) inde-
pendently of chemotherapy [11]. Moreover, in the context
of 5-fluorouracil therapy patients with MSS/MSI-L tumors
had improved overall survival, whereas no similar benefit
in outcome pertained to MSI-H tumors [2,12].
Various features of MMR deficient cancer cells as tolerance
to accumulate 5-fluorouracil adducts and conspicuous
lymfocytic infiltration in tumors have been put forward to
account for the opposing trends of relative resistance of
chemotherapeutic interventions, against the background
of a favourable natural history [13].
Whether microsatellite instability deregulates genes
related to tumor growth and response to 5-fluorouracil
therapy, however, has not been clarified. Two such
biomarkers thymidylate synthase (TS) [14-18] and dihy-
dropyrimidine dehydrogenase (DPD) [19] play key roles
for response to 5-fluorouracil therapy of colorectal cancer.
The main mode of action is through irreversible inhibi-
tion of TS, whereas the major part of an administered 5-
fluorouracil dose is catabolised by DPD. In addition,
these enzymes may be considered prognostic for the out-
come of colorectal cancer independently of chemotherapy
as they regulate tumor pyrimidine homeostasis by catalyz-
ing synthesis and degradation, respectively [14-22].
This retrospective study aimed to evaluate the association
of MSI and MMR deficiency with outcome and with
thymidylate synthase (TS) and dihydropyrimidine dehy-
drogenase (DPD) expression in tumors from 340 consec-
utive patients who were completely resected for colorectal




Consecutive patients completely resected for colon or rec-
tal carcinomas stages II-IV, who received adjuvant chemo-
therapy at Department of Oncology, Rigshospitalet,
Copenhagen University Hospital in the period February
1996 to December 2003 were included.
The adjuvant treatment was according to the Mayo regi-
men (Mayo Clinic, Rochester, MN), including bolus infu-
sion of 5-fluorouracil (425 mg/m2) and isovorin (10 mg/
m2) for 5 days, repeated every 4 weeks, for 6 courses. Data
on clinical and pathological characteristics and chemo-
therapy were obtained from surgical, pathological and
oncological records. Recurrence and survival data were
followed-up September 2007 (censoring date) using data-
bases on hospital admission and the National Central
Registry on death recording. The local research ethics
committee has approved this study and for the samples to
be used in research (KF01-201/03, 01-286965).Page 2 of 12
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Archival tumor samples were collected from the patholog-
ical departments serving the surgical departments that
referred cancer patients to Department of Oncology, Rig-
shospitalet. Out of 352 tumor specimens requested, 340
tumor specimens were accessible and contained repre-
sentative tumor tissue, that were evaluated as to the type
of carcinoma, degree of differentiation, perineural tumour
growth and vascular invasion using one section from each
block stained by routine heamatoxylin and eosin (HE)
staining.
Microsatellite analysis
Guided by microscopic examination of the HE stained
slide, areas with at least 50% tumor cells present were
grossly dissected from four 10 μm sections mounted onto
glass slides, and DNA was isolated and prepared for mic-
rosatellite analysis. Microsatellite instability was deter-
mined in tumor DNA without the need for matching
normal tissue DNA [23] using the highly specific panel of
five quasimonomorphic mononucleotide repeats NR-21,
NR-22, NR-24, BAT-25, and BAT-26 [23,24] in a penta-
plex polymerase chain reaction as previously described
[25]. For the purpose of prognostic evaluation microsatel-
lite status was categorized as MSS (stable) versus MSI
(instable) whether having instability in no (0) or more
(≥1) markers, respectively.
Immunohistochemistry
From the tissue specimens 2 mm cylinders were punched
out and collected in microarray paraffin blocks each con-
taining 40 samples. Tissue from normal kidney, liver and
lymph node was included in the tissue arrays serving as
reading frame and controls.
Sections of 4 μm were cut from the arrays and deparaffin-
ized in xylene and rehydrated. Antigen retrieval was per-
formed by immersing the slides in a 10 mM citrate buffer
(pH 6 for hMLH1 and pH 7 for hMSH2, hMSH6, and
hPMS2), and heating them in a microwave oven for 30
min at 95°C. Endogenous peroxidase was quenched by
incubation of samples with 0.3% hydrogen peroxide in
methanol. After washing in phosphate buffered saline
(PBS), the sections were placed in 20% normal goat serum
in PBS for 20 minutes to reduce non-specific staining. Sec-
tions were then incubated with monoclonal antibodies
raised against hMLH1 (clone G168-15, 1:50 dilution; BD
PharMingen, San Diego, CA), hMSH2 (clone NA27, 1:30
dilution; Oncogene Research Products, Darmstadt, Ger-
many), hMSH6 (clone 44, 1:200 dilution; BD Transduc-
tion Laboratories), or PMS2 (clone 37, 1:250 dilution; BD
PharMingen) for 1 hour at room temperature. TS and
DPD stainings were done as previously described [20].
Subsequently, visualization was performed using the
DAKO EnVision Duallink technique (DAKO, Glostrup,
Denmark) according to the manufacturer's instruction
and using diaminobenzidine as a chromogen.
Immunohistochemical staining of TS and DPD was
assessed semi-quantitatively. TS staining intensity was
scored (0–3) using the scale 0: no staining, 1: weak stain-
ing, 2: moderate staining, and 3: intense staining. Tumour
cells with the highest DPD intensity were evaluated and
assigned a score (0–3) using the scale 0: no staining, 1:
faint ambiguous staining, 2: partly staining of cell mem-
branes, 3: staining of cell membranes and cytoplasm.
MMR proteins were scored as either no or positive stain-
ing. During loss of expression of a MMR protein the het-
erodimer may degrade too resulting in distinct patterns of
absence of nuclear staining for each of the proteins
hMLH1 (hMLH1, hPMS2), hMSH2 (hMSH2, hMSH6),
and hMSH6 (hMSH6). Definite nuclear staining of adja-
cent non-tumor cells (e.g. lymphocytes, fibroblasts and
endothelial cells) in the tissue array served as an internal
positive control. Negative controls were performed by
omitting the primary antibodies and by application of an
isotype-matched non-reactive immunoglobulin in each
staining run. Tissue specimens were analysed blinded to
all other analyses and clinical information.
Statistics
The relationships between tumor microsatellite status and
clinicopathologic features were analyzed using Chi-square
test or Mann-Whitney U-test, as appropriate. Survival time
was calculated from the time point of the complete resec-
tion of the tumor. The outcome variables were recurrence
free survival (RFS), defined as time to relapse of primary
disease or death, whichever occurred first, and death from
any cause for overall survival (OS). Distributions of RFS
and OS were displayed using Kaplan-Meier methodology,
and univariate survival distributions were compared using
the log-rank test. Cox proportional hazard modeling was
used to evaluate the association of RFS and OS with clin-
icopathological characteristics and MSI and MMR status.
All candidate prognostic variables were initially entered
into the model, and non-significant (P > 0.1) variables
were subsequently rejected (step-down variable selec-
tion). Graphical methods were used to ascertain underly-
ing model assumptions as proportional hazards. The
interaction between TS or DPD expression and microsat-
ellite status with outcome was evaluated in a Cox model.
Multivariate logistic regression was used to test for the
association of MSI status with the independent variables
TS, DPD and clinicopathological characteristics. Kappa
statistics was performed for comparison of MSI and MMR
analyses. Two-sided P < 0.05 was considered statistically
significant. Statistics was performed with Statistica soft-
ware (Statsoft Inc. Tulsa, OK, USA).Page 3 of 12
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Clinicopathology, microsatellite instability and mismatch 
repair protein expression
Microsatellite status was assessed in 311 (92%) of 340
tumors. In the remainders analyses failed for technical
reasons partly because of DNA degradation in tumor
necrosis. In the microsatellite study sample 43 (13.8%)
tumors had MSI. In the MSI subset the frequencies of
mutated microsatellite loci were for NR-21 41 (95.3%),
NR-22 38 (88.4%), NR-24 28 (65.1%), BAT-25 42
(97.7%), and BAT-26 42 (97.7%), respectively. MSI
tumors had instability in at least three and in most cases
four markers, while MSS tumors had none.
Expression of mismatch repair proteins hMLH, hMSH2,
hMSH6 and hPMS2 was assessed in 306 (90%) tumor
specimens using immunohistochemistry. The analysis
failed in the remaining archival samples mainly because
of loss of tissue cylinders during sectioning of arrays.
Absence of repair protein expression was stated in 52
(17.0%) tumors. The coincidental absence of nuclear
staining of a repair protein and its heterodimer indicated
that loss of expression had primarily occurred for hMLH1
in 39 (12.7%), hMSH2 in 5 (1.6%), and for hMSH6 in 8
(2.6%) tumors.
Clinical and pathological characteristics according to mic-
rosatellite status are shown in Table 1. MSI tumors had a
bimodal age distribution with significantly more elderly
patients (P = 0.02) and few younger patients. Tumors with
MSI were poorly differentiated (P = 0.001). MSI tumors
were mainly located proximally to the splenic flexure in
ascending and transverse colon (P = 0.001), and had
minor risk of ileus at resection (P = 0.01). There were no
statistically significant differences (P > 0.05) according to
microsatellite status regarding gender, stage, vascular
tumor invasion, perineural tumor invasion, or tumors
complicated by perforation.
Microsatellite instability and mismatch repair protein 
expression
Compared to MSI status as the standard the immunohis-
tochemical analyses of MMR proteins had a sensitivity of
0.95, a specificity of 0.93, a positive predictive value of
0.67, and a negative predictive value of 0.99, that resulted
in an overall accuracy of 0.93. Correspondence between
MSI readings and immunohistochemical analyses led to a
Kappa value of 0.75.
Disease recurrence and survival
During follow up (median 6.1 years; range 4.1–11.3
years) 121 patients (36%) had documented recurrent dis-
ease and 153 patients (45%) have expired. Median overall
survival was 9.5 years, and the 5 year survival rate was
62%.
Microsatellite instability, mismatch repair protein 
expression and outcome
In univariate analyses of outcome according to MMR sta-
tus stratified by disease stage (Table 2), patients having
MMR deficient compared to MMR proficient tumors had
significantly lower risk of recurrence (HR = 0.5; 95% CI:
0.3–0.9; P = 0.006) (Figure 1a) and death (HR = 0.6; 95%
CI: 0.3–1.0; P = 0.04) (Figure 1b). In multivariate analysis
of outcome MMR deficient compared to MMR proficient
tumors were significantly associated with lower risk of
recurrence (HR = 0.4; 95% CI: 0.3–0.8 P = 0.003) and
death (HR = 0.5; 95% CI: 0.3–0.9; P = 0.02), when con-
trolling for the influence of other independent predictors
of recurrence; disease stage (P = 0.001), perineural inva-
sion (P = 0.05), and ileus (P = 0.0002).
Similarly, in univariate analyses of outcome according to
microsatellite status stratified by disease stage (Table 2),
patients with MSI compared to MSS tumors had signifi-
cantly lower risk of recurrence (HR = 0.4; 95%CI: 0.2–0.7;
P = 0.002) (Figure 2a) and death (HR = 0.5; 95% CI: 0.2–
0.9; P = 0.02) (Figure 2b). Also in multivariate analysis of
outcome MSI compared to MSS tumor patients had signif-
icantly lower risk of recurrence (HR = 0.3; 95% CI: 0.2–
0.7; P = 0.0007) (Figure 3a) and death (HR = 0.4; 95% CI:
0.2–0.9; P = 0.02) (Figure 3b) adjusted for the prognostic
influence of disease stage (P = 0.0001), vascular invasion
(P = 0.02), perineural invasion (P = 0.05), and ileus (P =
0.0002).
Microsatellite instability and association with TS and DPD 
expression
The distribution of biomarkers according to microsatellite
status (Table 1) indicated a direct relationship between
MSI and increasing TS staining intensity (P = 0.001),
while there was no evidence of an association with DPD
staining intensity (P = 0.1). Similar results applied to the
relationship between MMR status and expression of TS (P
= 0.0001) and DPD (P = 0.3).
Logistic regression testing relating MSI status and clinico-
pathological variables to the value of biomarkers as
dependent variables revealed statistically significant asso-
ciation with increasing TS expression (global P = 0.0001),
and non-significant association with DPD expression (P =
0.4).
Tests for interaction between biomarker expression and
MSI status to predict outcome, using Cox analysis, were
statistically significant for TS for recurrence (P = 0.002)
and overall survival (P = 0.02), and non significant for
DPD for recurrence (P = 0.5) and overall survival (P =
0.9). With adjustment for multiple comparisons of four
interactions considered, involving two biomarkers and
two outcomes, the test values for TS were statistically sig-Page 4 of 12
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overall survival (P = 0.1).
Discussion
In keeping with previous reports [2-4,6] and a meta-anal-
ysis [11] this study found a favourable outcome associ-
ated with MSI as compared to MSS of resected colorectal
carcinomas stage II-IV in the adjuvant setting. These find-
ings were based on uniform criteria for categorization of
microsatellite instability using the NCI recommended ref-
erence panel of five loci [24]. In addition, characterization
of mismatch repair competency by assessing expression of
four main mismatch repair proteins corroborated these
results. Others reported no prognostic significance of mic-
rosatellite instability in this setting, based on various cri-
teria for microsatellite status [5,26-29].
Initial investigations into the predictive role of microsat-
ellite instability showed similar improvement in outcome
from adjuvant 5-fluorouracil therapy irrespective of mic-
rosatellite status of the resected adenocarcinomas [28,30].
Inadvertantly biased treatment groups for comparison






No. (%) No. (%)
Gender
Male 21 (49) 138 (51) 0.9
Female 22 (51) 130 (49)
Age
<70 28 (65) 217 (81) 0.02
≥70 15 (35) 51 (19)
Tumor site
Proximal colon 36 (84) 68 (25) 0.001
Distal colon 6 (14) 145 (54)
Rectum 1 (2) 55 (21)
Stage
II 6 (14) 26 (10) 0.4
III 34 (79) 210 (78)
IV 3 (7) 32 (12)
Differentiation grade (WHO)
Well 5 (12) 88 (33) 0.001
Intermediate 7 (16) 121 (45)
Poor 31 (72) 59 (22)
Perineural tumor invasion
+ 5 (12) 53 (20) 0.5
- 19 (44) 137 (51)
not assessed 19 (44) 78 (29)
Vascular tumor invasion
V0 18 (42) 142 (53) 0.8
V1 8 (19) 58 (22)
Vx 17 (39) 68 (25)
Intestinal perforation at resection
yes 2 (5) 29 (11) 0.2
no 41 (95) 239 (89)
Bowel obstruction before resection
yes 1 (2) 44 (16) 0.01
no 42 (98) 224 (84)
Thymidylate synthase level
Low 12 (28) 218 (81) 0.001
High 30 (70) 47 (18)
not assessed 1 (2) 3 (1)
Dihydropyrimidine dehydrogenase level
Low 21 (49) 163 (61) 0.1
High 21 (49) 97 (36)
not assessed 1 (2) 8 (3)
*instable (MSI) or stable (MSS) microsatellitesPage 5 of 12
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improved outcome from adjuvant 5-fluorouracil in terms
of reduced recurrence rate and better overall survival
related to patients with microsatellite stable tumors only
[2,5,12,29,31-33], whereas the subset having MSI cancers
gained no similar beneficial effect from chemotherapy
[11]. Hence the prevailing evidence suggests that 5-fluor-
ouracil therapy should not be given to patients with MSI
colorectal cancer.
On these premises the outcome according to microsatel-
lite status in the present study can therefore be ascribed
mainly to the biology of MSI colorectal cancer and to a
lesser extent to antitumor response to 5-fluorouracil ther-
apy. Other clinicopathological features of the MSI carci-
nomas may contribute to the better prognosis. Hence the
minor risk of bowel obstruction associated with right
sided tumors is an independent favourable prognostic
variable. Moreover the generally lower staging at diagno-
sis is taken to indicate minor propensity of MSI tumors to
metastasize [11,31,34,35]. Possibly the decreasing fre-
quency of MSI by stage was not as evident in this cohort
because of selection. According to the current treatment
algorithm most stage II cancers are not referred for adju-
vant chemotherapy unless they have additional poor
prognostic factors.
In multivariate analysis the outcome of MSI tumor
patients was independent of the TS and DPD levels, sug-
gesting that differential expression of these enzymes could
not account for the favourable natural history nor the
resistance to chemotherapy [2,5,12,29,31-33].
The major part of an administered dose of 5-fluorouracil
is catabolized by dihydropyrimidine dehydrogenase
(DPD) into 5,6-dihydrofluorouracil, before it can be con-
verted to the active metabolite fluoro-2'-deoxyuridine-
monophosphate that irreversibly inhibits thymidylate
synthase. Also the intracellular conversion to 5-fluorouri-
dine and 5-fluoro-2'-deoxyuridine and corresponding
phosphates for incorporation into RNA and DNA, respec-
tively, have cytotoxic effect [13]. The similar magnitude of
DPD expression regardless of tumor microsatellite status
is consistent with MMR deficient cells accumulating 5-
fluorouracil adducts in DNA [13], which is possibly toler-
ated due to inability to recognise adducts and to initiate
apoptosis.
The correlation between high TS expression and microsat-
ellite instability noticed in this and other studies [36,37]
should be interpreted cautiously, as it may not explain
prognostic and chemotherapeutic response characteristics
of MSI and MMR deficient tumors. Accordingly high TS
expression has generally been associated with early dis-
ease recurrence independently of chemotherapy [14-
18,21], while also being related to improved outcome
from adjuvant 5-fluorouracil treatment [14-19]. On the
other hand, low TS expression has been related to low
spontaneous recurrence rate [14-18,21], while indicating
relative 5-fluorouracil resistance as well [14-19].
Unlike previous reports [5,38] the potential interaction
between TS expression and microsatellite status with dis-
ease recurrence was based on a marginal direct relation-
ship between TS level and outcome for patient with MSI
tumors, which did not apply to the MSS subset. The low
metastatic capacity [11,31,34,35] and high apoptotic
index [39] of MSI tumors may counterbalance metabolic
features otherwise linked to poor prognosis [14-18,21].
Earlier reports on the relationship between TS intensity
and microsatellite instability have been conflicting [5,36-
38,40-44] arguing either for a direct correlation [36,37] or
no such association [5,38,41,42]. The discrepancy may
partly relate to lack of consistency in criteria defining mic-
rosatellite instability, as some studies were based on sin-
Table 2: Outcome according to microsatellite instability and mismatch repair deficiency stratified by disease stage.
Recurrence free survival Overall survival
No. Events Hazard ratio (95% CI) P Events Hazard ratio (95% CI) P
Microsatellite status*
All stages 311 113 0.4 0.2–0.7 0.002 138 0.5 0.2–0.9 0.02
II 32 8 - - - 13 - - -
III 244 81 0.5 0.3–0.9 0.04 101 0.6 0.3–1.2 0.2
IV 35 24 - - - 24 - - -
Mismatch repair competence*
All stages 306 149 0.5 0.3–0.9 0.006 132 0.6 0.3–1.0 0.04
II 36 14 - - - 13 - - -
III 241 112 0.6 0.4–1.0 0.04 100 0.7 0.4–1.2 0.2
IV 29 23 - - - 19 - - -
*hazard ratios for instable (MSI) relative to stable (MSS) microsatellites, and mismatch repair deficient relative to proficient tumors.Page 6 of 12
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Recurrence free survival (a) and overall survival (b) according to mismatch repair deficiency from loss of either hMSH2, hMSH6, or hMLH1 in colorectal cancers of patients completely resected and adjuvantly treated with 5-fluorouracilFig e 1
Recurrence free survival (a) and overall survival (b) according to mismatch repair deficiency from loss of 
either hMSH2, hMSH6, or hMLH1 in colorectal cancers of patients completely resected and adjuvantly treated 
with 5-fluorouracil. Censored data (+).
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Recurrence free survival (a) and overall survival (b) by instable (MSI) and stable (MSS) microsatellites in tumors of colorectal cancer patients completely resected and adju ntly treated with chemotherapyFig e 2
Recurrence free survival (a) and overall survival (b) by instable (MSI) and stable (MSS) microsatellites in 
tumors of colorectal cancer patients completely resected and adjuvantly treated with chemotherapy. Censored 
data (+).
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Forest plots displaying multivariate Cox analysis of variables prognostic to recurrence free survival and overall survival follow-ing complete resection of colorectal cancer and adjuvant chem therapyi ure 3
Forest plots displaying multivariate Cox analysis of variables prognostic to recurrence free survival and overall 
survival following complete resection of colorectal cancer and adjuvant chemotherapy. The prognostic variables 
included clinicopathological characteristics, tumor microsatellite status, expression of thymidylate synthase (TS) and dihydro-
pyrimidine dehydrogenase (DPD).
BMC Cancer 2009, 9:25 http://www.biomedcentral.com/1471-2407/9/25gle microsatellite marker [38,40] whereas others [5,36,44]
applied more restricted criteria [24]. Also technical mat-
ters regarding immunohistochemical assessment of TS
expression may have led to different results. While 24% of
cases in this cohort had high TS score, the proportion in
other studies has ranged between 19–77% of colorectal
cancers in the adjuvant setting [45].
As prospective trials usually exclude elderly patients [5],
also the age distributions of patient cohorts may have var-
ied between studies. This raises the question whether high
TS expression is confined to either inherited or sporadic
MSI cancers that usually arise at an average age in the mid-
forties or beyond the age of 70 years, respectively [46].
Difference in TS expression might be of significance to
varying outcome of MSI tumors seen in the context of
inherited repair deficiency [33].
Significantly higher TS score in tumors deficient of
hMLH1 as compared to those deficient of hMSH2 or
hMSH6, actually did support the notion that TS expres-
sion may vary according to the etiology of mismatch
repair deficiency.
Though the pattern of microsatellite instability and result-
ant influence on gene deregulation may depend on the
mechanism of mismatch repair deficiency, no causal con-
nection can be deduced from the high TS expression
found in MSI tumors. The fact that microsatellite instabil-
ity not being involved in recombinant events leading to TS
gene variability [40,43,44] suggests that the phenomenon
is rather of secondary character. Thus the somewhat para-
doxical mucinous histology and poor differentiation of
MSI tumors [38,41] have metabolic traits implying higher
intensity and diffuse pattern of TS expression [20].
Taken together there are no evidence to suggest direct
influence of microsatellite instability on DPD or TS
expression, nor that differential expression of these
enzymes mediates the features for tumor biology or 5-
fluorouracil resistance of MSI carcinomas.
The discrepancy in results obtained with the MSI and
immunohistochemical methods may have various causes.
The subsets analysed with either methods in this study is
partly overlapping for technical reasons as indicated in
results section. The most significant limitation of immu-
nohistochemistry is the semiquantitative nature of immu-
nostaining and the loss of sensitivity secondary to
antigenic alterations caused by fixation procedures. Faint
staining may be considered non-specific leading to higher
sensitivity and lower specificity for defining MMR defi-
ciency, or vice versa. Moreover a mutant protein product
can be expressed and detected by immunohistochemistry.
Conversely MMR protein mutations may occur in tumors
displaying no MSI. These analytical shortcomings pre-
clude that the methods may unambiguously reflect each
other.
Conclusion
Microsatellite instability due to MMR deficiency is one of
the main biomarkers in colorectal cancer, as it not only
indicates the pathogenesis, but also provides information
on prognosis and prediction of response to chemother-
apy. Future investigations into gene targets for microsatel-
lite instability-driven deregulation may clarify the
molecular foundation for the distinct clinicopathological
characteristics of MSI carcinomas.
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